CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019

CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, discussing CytoDyn’s PRO140 monoclonal antibody therapy for HIV and cancer.The company is at a key inflection point, with potential FDA approval for PRO140 for treating HIV expected in 2019. Dr. Pourhassan explains the PRO140 technology, its numerous advantages over current HIV therapies on the market, market potential, as well as expanding PRO140’s indications for treating cancer.  Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Jan 11, 2019

Embed this episode

Attribution link and audio player

Ready to play

CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019

0:00 28:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Wall Street Reporter?

This episode is 28 minutes long.

When was this Wall Street Reporter episode published?

This episode was published on January 11, 2019.

Can I download this Wall Street Reporter episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!